http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-033378-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bef96a52ca9eaf6230a857ba74af9a1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 |
| filingDate | 2001-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-033378-A1 |
| titleOfInvention | DERIVATIVE OF ANTIGEN OF PROSTASE, NUCLEIC ACID SEQUENCE THAT CODIFIES IT, VECTOR OF EXPRESSION CONTAINING THE PREVIOUS, CELLULATED BONE TRANSFORMED WITH SUCH SEQUENCE OF A NUCLEIC ACID OR SUCH VECTOR, VACCINE THAT UNDERSTANDS THE NUMBER OF DERIVATIVE OF NUT USE OF |
| abstract | Prostase antigen derivatives are described and claimed, where the prostase sequence has a mutation at the active site of the protein. Preferably, a histidine mutation ------ Alanine is introduced into the active site. The mutated prostase protein can be associated by fusion with a molecule, for example, by fusion with an immunological fusion molecule by fusion with a molecule that enhances expression. For example, the fusion molecule is the NS1 protein from influenza or a fragment thereof. The antigen may comprise modified thiol moieties, which may be carboxyamidated or carboxymethylated. The protein may further comprise affinity signals; a nucleic acid sequence encoding a protein as described; an expression vector containing said nucleic acid; host cells that are transformed with a nucleic acid sequence or with said vector. Vaccines that contain that protein or said nucleic acid. Vaccines may also comprise adjuvants and / or cytokines or immunostimulatory chemokines. The adjuvants may comprise one or more of 3D-MPL, QS21, oligonucleotides with CpG or polyethylene ethers or esters and the protein is preferably included in a water-in-oil emulsion or an oil-in-water emulsion as a vehicle. Vaccines may also comprise one or more different antigens. The use of the protein or nucleic acid comprises the manufacture of vaccines to immunotherapeutically treat patients suffering from prostate cancer or other tumors associated with prostase and the method for the production of the protein comprising transforming host cells with the nucleic acid sequence. , express said sequence and isolate the desired product. In turn, the process for the production of vaccines comprising the steps of purifying the prostase protein (or derivatives thereof) by the above procedure, and mixing the resulting protein with adjuvants, diluents or other pharmaceutically acceptable and appropriate excipients. |
| priorityDate | 2000-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.